ArticleJournal of clinical microbiology2026
Performance of the LIAISON PLEX gram-positive blood culture assay for identifying bacterial pathogens and resistance genes in blood cultures.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid and accurate identification of gram-positive bacteria that cause bloodstream infections using molecular assays drives antibiotic optimization and patient management. This multisite study evaluated the performance of LIAISON PLEX Gram-Positive Blood Culture (BCP) Assay, a qualitative multiplexed diagnostic molecular test that detects and differentiates 13 gram-positive bacterial targets and 4 antibiotic resistance markers (AMRs) from blood culture bottles showing gram-positive bacterial growth. Clinical performance was examined on 509 prospective, 162 pre-selected, and 225 contrived blood culture samples. The overall valid rate of the tests was 99.9%. The overall sensitivity/PPA and specificity/NPA for all targets were 98.5% and 99.7%, respectively. In the inclusivity study, 183 of 184 tested strains were detected. Cross-reactivity was observed in five bacteria among a collection of 103 off-panel species. The LIAISON PLEX BCP Assay demonstrated compatibility with various types of blood culture bottles by three manufacturers. Target organism detection was not affected by the presence of six potential interfering substances. Both sensitivity and specificity were maintained in the setting of polymicrobial infections with different organisms. The LIAISON PLEX BCP Assay allows fast detection of gram-positive organisms and their AMR genes from positive blood cultures with high accuracy and reliability.IMPORTANCEThe use of molecular assays has improved the diagnosis of bloodstream infections because of their much-reduced turnaround time and high performance compared to conventional culture workups. The early detection of clinically significant resistance markers has direct impacts on antibiotic optimization and patient isolation. This multisite study demonstrated excellent sensitivity and specificity of the LIAISON PLEX Gram-Positive Blood Culture Assay that detects and differentiates 13 gram-positive bacterial targets and 4 antibiotic resistance markers. The assay performance was assessed clinically and analytically using large and diverse sets of samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.